Exhibit 090 ยท Record comparison and meta-analysis
Selective publication of antidepressant trials, newer drugs: follow-up comparison with FDA records
Within negative trials, transparent reporting increased from 11% to 47%.
Examined 30 trials of four newer antidepressants (13,747 participants). All 15 FDA-positive trials were transparently published. Of 15 negative trials, seven were transparently published, six were unpublished and two were presented as positive. Transparent publication of negative trials rose from 11% in the authors' older comparison to 47%. Standardized effect size was 0.24 in FDA records and 0.29 in journals. The study covered efficacy outcomes and a small drug sample; it did not establish equivalent improvement in safety reporting.
- Source
- Turner et al., PLOS Medicine
- Date
- 2022
- Quoted from
- Abstract-level summary (Methods and findings), PLOS Medicine 2022
- Grade
- Peer-reviewed
- Document
- https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003886
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit